TD Cowen began coverage on shares of Sionna Therapeutics (NASDAQ:SION – Get Free Report) in a report released on Tuesday, MarketBeat reports. The brokerage set a “buy” rating on the stock.
A number of other equities research analysts have also weighed in on the stock. Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a report on Tuesday. They set a “buy” rating and a $32.00 target price on the stock. Guggenheim began coverage on shares of Sionna Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 price objective on the stock.
Get Our Latest Report on Sionna Therapeutics
Sionna Therapeutics Stock Up 11.4 %
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Health Care Stocks Explained: Why You Might Want to Invest
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Find and Profitably Trade Stocks at 52-Week Lows
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
